Multinationals Score Three Out Four New China Priority Reviews

Eight drugs from foreign multinationals, including Amgen’s Rapatha, Takeda’s Takecab, Sanofi’s Aubagio and UCB’s Cimzia, are among 12 products awarded priority new drug approval reviews in China under a scheme to speed up approvals and patient access that is also benefiting some domestic players.

China globe
MNCs ACCOUNT FOR TWO THIRDS OF CHINA PRIORITY REVIEWS • Source: Shutterstock

The China State Drug Administration's Center for Drug Evaluation (CDE) has released its latest list of new drugs awarded priority approval reviews, which shows that eight out of the 12 products so designated are from foreign multinationals, indicating that regulatory reform policies to encourage quicker approvals and speed up patient access are taking hold, and quickly.

Among the products newly granted priority status was Takeda Pharmaceutical Co. Ltd.'s Takecab (vonoprazan fumarate, TAK-438), for which the...

More from China

More from Asia